In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $30.00.
Patrick Trucchio has given his Buy rating due to a combination of factors including Voyager Therapeutics’ progress in gene therapy and biologics for neurological diseases. The company is well-capitalized with a cash runway extending into mid-2027 and has strategic partnerships with major firms like Neurocrine, Novartis, and Alexion, which could lead to milestone payments of up to $8.2 billion.
Additionally, Voyager’s robust pipeline and upcoming catalysts, such as the presentation of non-human primate data on VY1706 and the 2025 IND filings for Parkinson’s and Friedreich’s ataxia programs, add to its potential. The development of VY7523, an anti-tau antibody, is also promising, with initial trials showing favorable safety and pharmacokinetics. These factors, combined with the potential for significant revenue generation and validation from other anti-tau programs, underpin Trucchio’s positive outlook on Voyager’s stock.
Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Beam Therapeutics. According to TipRanks, Trucchio has an average return of -4.0% and a 30.25% success rate on recommended stocks.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $11.00 price target.